Puerperal insertion of a copper-releasing and a levonorgestrel-releasing intrauterine contraceptive device.
A copper-releasing IUD and levonorgestrel-releasing IUDs releasing 30 micrograms and 10 micrograms levonorgestrel per day were inserted six weeks after delivery in 110 volunteers. During the treatment, events and patterns of bleeding were recorded and plasma levonorgestrel concentrations were measured. The number of events in one year of follow-up was very low, four removals out of 40 in the copper-releasing IUD group and five removals out of 70 in the levonorgestrel-releasing IUD group. Bleeding and spotting was significantly more common after insertion of a levonorgestrel-releasing IUD than a copper-releasing IUD, but it was scanty and well-tolerated. After three months, levonorgestrel-releasing IUD patients had less bleeding and spotting than the copper-releasing IUD patients. No pregnancies occurred during the study period. There were two uterine perforations with a uterine sound at the insertion. In the 30-micrograms per day levonorgestrel-releasing IUD group, initially high plasma levonorgestrel concentrations reached a plateau four weeks after the insertion. In the 10-micrograms per day levonorgestrel-releasing IUD group, the plasma concentrations of levonorgestrel stabilized after the initial two weeks.
D000328:Adult; D001942:Breast Feeding; D003277:Contraceptives, Oral, Combined / Q000008:administration & dosage / Q000097:blood; D005260:Female; D006801:Humans; D007433:Intrauterine Device Expulsion; D007434:Intrauterine Devices / Q000009:adverse effects; D007435:Intrauterine Devices, Copper / Q000009:adverse effects; D016912:Levonorgestrel; D008796:Metrorrhagia / Q000209:etiology; D008875:Middle Aged; D008881:Migraine Disorders / Q000209:etiology; D009644:Norgestrel / Q000008:administration & dosage* / Q000097:blood; D049590:Postpartum Period; D011247:Pregnancy
D003277:Contraceptives, Oral, Combined; D009644:Norgestrel; D016912:Levonorgestrel